Anti-angiogenic therapy versus dose-dense paclitaxel therapy for frontline treatment of epithelial ovarian cancer: review of phase III randomized clinical trials.

Slaughter, Katrina N; Moore, Kathleen N; Mannel, Robert S

Slaughter, Katrina N; Moore, Kathleen N; Mannel, Robert S.

Affiliation

Slaughter KN; Department of Obstetrics and Gynecology, Oklahoma University Health Sciences Center, 800 N.E. 10th Street, Oklahoma, OK, 73103, USA.

Curr Oncol Rep ; 16(11): 412, 2014 Nov.

Article in En | MEDLINE | ID: mdl-25292279

Subject(s)

Angiogenesis Inhibitors/therapeutic use; Antineoplastic Agents, Phytogenic/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasms, Glandular and Epithelial/drug therapy; Ovarian Neoplasms/drug therapy; Paclitaxel/administration & dosage; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Protein Kinase Inhibitors/therapeutic use; Randomized Controlled Trials as Topic

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Paclitaxel / Neoplasms, Glandular and Epithelial / Angiogenesis Inhibitors / Antineoplastic Agents, Phytogenic Type of study: Clinical_trials / Prognostic_studies Limits: Female / Humans Language: En Journal: Curr Oncol Rep Journal subject: NEOPLASIAS Year: 2014 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google